Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 17, 2017 - Issue 4
Submit an article Journal homepage
343
Views
10
CrossRef citations to date
0
Altmetric
Original Research

National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007–2016 in South Korea

Eun-Sook KimSchool of Pharmacy, Sungkyunkwan University, Suwon, South KoreaORCID Iconhttp://orcid.org/0000-0002-1559-2868View further author information
ORCID Icon,
Jung-Ae KimSchool of Pharmacy, Sungkyunkwan University, Suwon, South KoreaORCID Iconhttp://orcid.org/0000-0003-4369-2978View further author information
ORCID Icon &
Eui-Kyung LeeSchool of Pharmacy, Sungkyunkwan University, Suwon, South KoreaCorrespondence[email protected]
View further author information
Pages 401-409 | Received 31 Oct 2016, Accepted 22 Dec 2016, Published online: 03 Jan 2017

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Sungju Kim, Jinhong Kim, Hyunyoung Cho, Kyungmin Lee, Chiyoung Ryu & Jong Hyuk Lee. (2021) Trends in the pricing and reimbursement of new anticancer drugs in South Korea: an analysis of listed anticancer drugs during the past three years. Expert Review of Pharmacoeconomics & Outcomes Research 21:3, pages 479-488.
Read now
Naina R. Verghese, Jon Barrenetxea, Yukti Bhargava, Sagun Agrawal & Eric Andrew Finkelstein. (2019) Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview. Journal of Market Access & Health Policy 7:1.
Read now

Articles from other publishers (8)

Hyungmin Kim, Brian Godman, Hye-Young Kwon & Song Hee Hong. (2023) Introduction of managed entry agreements in Korea: Problem, policy, and politics. Frontiers in Pharmacology 14.
Crossref
Yitong Wang, Tingting Qiu, Mateusz Nikodem, Clément Francois & Mondher Toumi. (2022) A systematic literature review of revealed preferences of decision-makers for recommendations of cancer drugs in health technology assessment. International Journal of Technology Assessment in Health Care 38:1.
Crossref
Seung Mi Lee, Heui Jae Kim, David Suh, Kyung-In Joung, Eun Suk Kim, Hee Jung Back, Jun Young Kwon, Man-Jae Park & Dong Churl Suh. (2021) Use of budget savings from patent expiration of cancer drugs to improve affordability and accessibility. BMC Health Services Research 21:1.
Crossref
Kai‐Hsin Liao, Bor‐Sheng Ko, Liang‐Kung Chen & Fei‐Yuan Hsiao. (2020) Factors Affecting Usage Levels and Trends of Innovative Oncology Drugs Upon and After Reimbursement Under Taiwan National Health Insurance: Interrupted Time Series Analysis. Clinical and Translational Science 13:6, pages 1288-1297.
Crossref
Carolina Zampirolli Dias, Brian Godman, Ludmila Peres Gargano, Pâmela Santos Azevedo, Marina Morgado Garcia, Maurílio Souza Cazarim, Laís Lessa Neiva Pantuzza, Nelio Gomes Ribeiro-Junior, André Luiz Pereira, Marcus Carvalho Borin, Isabella de Figueiredo Zuppo, Roberto Iunes, Tomas Pippo, Renata Curi Hauegen, Carlos Vassalo, Tracey-Lea Laba, Steven Simoens, Sergio Márquez, Carolina Gomez, Luka Voncina, Gisbert W. Selke, Livio Garattini, Hye-Young Kwon, Jolanta Gulbinovic, Aneta Lipinska, Maciej Pomorski, Lindsay McClure, Jurij Fürst, Rosana Gambogi, Carla Hernandez Ortiz, Vânia Cristina Canuto Santos, Denizar Vianna Araújo, Vânia Eloisa Araujo, Francisco de Assis Acurcio, Juliana Alvares-Teodoro & Augusto Afonso Guerra-Junior. (2020) Integrative Review of Managed Entry Agreements: Chances and Limitations. PharmacoEconomics 38:11, pages 1165-1185.
Crossref
Yi‐Ru Shih, Kai‐Hsin Liao, Yen‐Hui Chen, Fang‐Ju Lin & Fei‐Yuan Hsiao. (2020) Reimbursement Lag of New Drugs Under Taiwan's National Health Insurance System Compared With United Kingdom, Canada, Australia, Japan, and South Korea. Clinical and Translational Science 13:5, pages 916-922.
Crossref
Ji Ryoun Gong, Donghwan Lee, Kyung-Min Lim & SeungJin Bae. (2020) Are Recently Evaluated Drugs More Likely to Receive Positive Reimbursement Recommendations in South Korea? 11-year Experience of the South Korean Positive List System. Clinical Therapeutics 42:7, pages 1222-1233.
Crossref
Peter Ghijben, Yuanyuan Gu, Emily Lancsar & Silva Zavarsek. (2017) Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review. PharmacoEconomics 36:3, pages 323-340.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.